01 Oct 2026, 08:47 IST
Emcure Pharmaceuticals Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · Buy · target 2,300
The report lists Emcure Pharma as a Focus Investment Idea with a Buy rating, CMP Rs 1,943 and target Rs 2,300, implying 18% upside.
From MOStMarketOutlook01102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.